Rehan Hussain is an Ophthalmology physician. OpenAlex indexes 70 publications with 1,906 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1530 N Randall Rd Ste 202
Elgin, IL 601237879
Telephone
847-488-1030Provider last certified this registry record 19 May 2022.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year20258 payments
- Astellas Pharma US IncProgram year20254 payments
- Regeneron Healthcare Solutions, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
88.9%Antineovascularisation agents83.7%Faricimab-svoa100%Part B, office-administered≥85 patientsComplement Inhibitor2.7%Avacincaptad pegol100%Part B, office-administered≥12 patients+ 4 more classes in this area
Cancer & immunology
10.4%Vascular Endothelial Growth Factor Inhibitor6.3%Aflibercept60%Bevacizumab40%Part B, office-administered≥234 patientsComplement Inhibitor4.2%Pegcetacoplan100%Part B, office-administered≥20 patientsMusculoskeletal
0.3%Cyclooxygenase Inhibitor0.3%Ketorolac Tromethamine100%Part D≥52 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
Nature Communications
2024 - Tyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?
International Ophthalmology Clinics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”